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Abstract
Background: Esophageal adenocarcinoma (EA) incidence in many developed countries has increased dramatically over four
decades, while survival remains poor. Persons with Barrett’s esophagus (BE), who experience substantially elevated EA risk,
are typically followed in surveillance involving periodic endoscopy with biopsies, although few progress to EA. No medical,
surgical or lifestyle interventions have been proven to safely lower EA risk.
Design: We investigated whether smoking, obesity or alcohol could predict progression to EA in a prospective cohort of 411
BE patients. Data were collected during personal interview. Adjusted hazard ratios (HR) were estimated using Cox
regression.
Results: 39% had body mass index (BMI) over 30 and 64% had smoked cigarettes. Main analyses focused on those with at
least 5 months of follow-up (33,635 person-months), in whom 45 developed EA. Risk increased by 3% per year of age (trend
p-value 0.02), with approximate doubling of risk among males. EA risk increased with smoking pack-years (trend p-value
0.04) and duration (p-value 0.05). Compared to never-smokers, the HR for those in the highest pack-year tertile was 2.29
(95%CI 1.04–5.07). No association was found with alcohol or BMI, whereas a suggestion of increased risk was observed in
those with higher waist-hip ratio, especially among males.
Conclusion: EA risk significantly increased with increasing age and cigarette exposure. Abdominal obesity, but not BMI, was
associated with a modest increased risk. Continued follow-up of this and other cohorts is needed to precisely define these
relationships so as to inform risk stratification and preventive interventions.
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Introduction
A rapid increase in incidence of and mortality from esophageal
adenocarcinoma (EA) has been observed over the past four
decades in the Western world [1–4]. Although the absolute
incidence of EA varies dramatically by gender and race, few
demographic groups have been spared from the increases.
Moreover survival of persons with EA remains abysmal, with
most succumbing to the disease within a year [5,6]. Extensive
research has identified the likely main causes of most EAs,
implicating obesity, cigarette smoking, reflux and, to a lesser
extent, diet as potentially modifiable etiologic factors [7].
Additionally, a growing number of observational studies suggest
that aspirin and other non-steroidal anti-inflammatory drugs
(NSAID) may be effective in reducing the risk of EA [8,9], even in
those who have high-grade dysplasia or significant genetic
abnormalities [10].
Barrett’s esophagus (BE), a columnar intestinal metaplasia of the
lower end of the esophagus that develops in approximately 10–
15% of patients with gastro-esophageal reflux, is a relatively easily-
discerned precancerous condition associated with a 30-fold or
higher increase in EA incidence [11–13]. BE can be found in most
individuals with EA, implying that it is a precursor in neoplastic
progression [11]. Consequently, extensive efforts have long been
undertaken by clinicians to identify persons in the general
population who have BE and enroll them into a long-term cancer
surveillance program, in the hope of identifying early-stage
esophageal cancers amenable to surgical cure. Some studies have
shown that EA’s diagnosed in such surveillance programs have
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diagnosed outside of such programs [14]. Although the risk of EA
among persons with BE is increased relative to the general
population, the absolute risk of individuals with BE progressing to
EA remains low, approximately 0.4–0.7% per year [15,16]. It is
not yet clear why only some persons with BE undergo neoplastic
changes in their Barrett’s segment and progress to cancer, while in
most others it remains a relatively benign condition throughout
their life.
Clinical and demographic factors that have shown some
promise in being predictive of malignant transformation in BE
are male gender [17,18], increasing age [17], length of Barrett’s
segment [19–22], duration of BE [20], and size of hiatal hernia
[21]. Decreased risk of progression has also been shown among
aspirin and NSAID users [8,9] and consumers of multivitamins,
vitamin C, and vitamin E [23]. If individuals at high risk of
neoplastic progression can be more accurately distinguished from
those who are likely to follow a benign course (risk stratification),
using host and lifestyle factors combined with validated markers of
risk from serum and esophageal tissue, then substantial improve-
ment in clinical management of BE could be achieved.
A number of population-based case-control studies and pooled
analyses have examined the effect of smoking and obesity on EA
development, [24,25], but the stage(s) at which they act are largely
unknown. While several studies have examined the associations
between smoking, obesity and development of BE [26,27], very
few have looked at whether cigarette smoking and obesity promote
development of EA among persons who already have BE.
Moreover, some of these studies were limited by their number of
EA cases, thus necessitating further evidence [20,22,28]. We
sought to investigate the associations between measures of
cigarette smoking, alcohol, and obesity and risk of progression to
EA in a prospective cohort study of 411 patients with BE.
Methods
Study participants
This report is based on participants of the Seattle Barrett’s
Esophagus Study (SBES), a prospective cohort of BE patients
originally established in 1983 [10,29]. Each participant in this
cohort undergoes periodic endoscopic surveillance with multiple
biopsies of the Barrett’s segment, as per a standard protocol
[11,30]. In 1995, the protocol was expanded to include an
extensive personal interview, dietary and anthropometric assess-
ments and collection of blood samples in addition to the periodic
endoscopies with biopsies. Ongoing participants underwent this
expanded evaluation at their first clinical visit on or after Feb 1,
1995; for the current report this is referred to as the baseline
evaluation. At subsequent clinical visits, shorter personal inter-
views updated information collected at the baseline evaluation.
This report is based on SBES participants enrolled for observation
between February 1, 1995 and September 30, 2009. During this
period, 427 participants with BE and no history of esophageal
cancer were interviewed, of whom 411 (96.3%) had at least one
follow-up visit and thus were eligible for analyses. This study was
approved by the Institutional Review Boards at the University of
Washington and Fred Hutchinson Cancer Research Center.
Baseline exposure assessment
At the baseline evaluation, each participant underwent a
structured personal interview conducted in person by trained
staff. The interview lasted approximately 45 minutes and data
regarding known and suspected risk factors for EA was collected.
Information on participants’ medical, family, and medication
history (along with current medication use), tobacco use, beverage
consumption, and diet was collected in addition to their
demographics. At this time anthropometric measurements were
taken by trained staff. The participants also provided fasting blood
samples prior to the endoscopy. Follow-up assessments occurred at
six month to two year intervals depending on the patients’ risk of
developing EA (based on histologic and flow cytometric assess-
ments) with high-risk patients returning every six months [31].
These follow-up evaluations included endoscopy, a shorter
interview with anthropometric measurements, and blood collec-
tion.
To collect data on smoking habits, participants were asked if
they had smoked at least one cigarette/day for six months or
longer (ever regular use), the intensity with which they smoked
(number of cigarettes/day), duration for which they had been
smoking and time since quitting. Cumulative pack-years of
smoking were calculated based on the number of cigarette packs
smoked per day and the number of years smoked. We calculated
the number of alcoholic drinks consumed per day by combining
participants’ responses for beer, wine and liquor consumption. In
models testing the association with alcohol, we used a categorical
variable for total alcohol as well as for specific beverage intake. A
history of aspirin and other NSAID use was collected at baseline
interview, and updated at each follow-up visit as previously
reported [10,29].
Anthropometric measurements including height, weight, waist
circumference and hip circumference were measured at baseline
and at every follow-up visit using a standardized protocol. Waist
circumference was measured at the waist at the level of the iliac
crest. Hip circumference was measured at the largest circumfer-
ence around the buttocks. Body mass index (BMI) was calculated
as weight in kilograms divided by height in meters squared (kg/m
2)
and categorized into four pre-defined categories: #25, .25-#30,
.30-#35 and .35. The waist and hip circumferences were used
to calculate the waist-hip ratio (WHR) and categorized into sex-
specific quartiles based on all participants.
Ascertainment of end points
Biopsies taken during follow-up visits were used to assess the
presence of EA. The methods for endoscopy and biopsy have been
described previously [31–33]. Briefly, four-quadrant biopsies were
obtained at 2 cm intervals from the Barrett’s segment (1 cm
intervals for those with history of high-grade dysplasia) and were
fixed, processed and interpreted by a single pathologist blinded to
the exposure status. Individuals with high grade dysplasia at their
initial endoscopy (80/411 participants; 19.46%) were re-endos-
coped twice more within 4 months so as to detect any occult
cancers missed at baseline endoscopy. At each follow-up visit,
participants were classified according to the maximum histological
abnormality present (BE, low-grade dysplasia, high-grade dyspla-
sia or EA). The study end-point for this report was development of
EA, defined histologically as invasion of neoplastic epithelium
beyond the basement membrane of the esophageal mucosa into
the surrounding lamina propria, muscularis mucosa or submucosa
[31].
Statistical analysis
Hazard ratios (HRs) and 95% confidence intervals (CI) were
estimated using Cox proportional hazards regression. Time to EA
development was used as the underlying time metric with entry
and exit times defined as the date of baseline visit endoscopy, and
date of endoscopic cancer diagnosis or last follow-up, respectively.
We evaluated the association between anthropometric measures
and EA by including them as continuous variables in the Cox
Predictors of Progression in Barrett’s Esophagus
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quartiles (WHR, waist, and hip circumferences) of the respective
variables. Associations between cigarette smoking and EA were
analyzed based on ever use, smoking duration, smoking intensity
and cumulative exposure to smoking based on pack-years. In
evaluation of these associations, never-smokers of cigarettes were
used as a reference group and the associations were tested in
tertiles of the various smoking-related variables. Alcohol-related
analyses included association of EA with categorical variables for
total alcohol intake as well as individual beverage types (beer, wine
and liquor). All models were adjusted for age, gender, and NSAID
use. The anthropometry-related models were also adjusted for
smoking status; the tobacco-related models were adjusted for
baseline WHR and the alcohol-related models were adjusted for
smoking and baseline WHR. Tests for trend were based on the
likelihood-ratio test associated with addition of the variable under
consideration in its continuous form. Effect modification was
examined through stratified analyses and the inclusion of
interaction terms in regression models. All p-values presented in
this paper are two-tailed and p-values less than 0.05 were
considered statistically significant. The proportional hazards
assumption was confirmed by computing interaction terms for
covariates with time and testing them for statistical significance at
the 0.05 level. Analyses were performed with the STATA
statistical package, release 11.
Results
During the study period, 427 participants with BE were enrolled
into the SBES cohort; of these 16 did not yet have any follow-up
visits and were excluded from the analyses. Participant character-
istics for the remaining 411 persons are shown in Tables 1 and 2.
Consistent with demographics of the disease, Caucasians (96.6%)
and males (81.3%) made up the majority of the cohort. The
percentage of males in the cohort was slightly higher than reported
in other BE studies [34]. The mean age of the cohort was 61.2
years. A total of 39.2% of the participants had a BMI greater than
30 kg/m
2, with 8.8% having a BMI over 35 kg/m
2. Most were
current or former cigarette smokers (64%), reported having
regularly used alcohol in their lifetime (81.5%), and had regularly
taken NSAID at some point in their life (60.6%).
Table 2 summarizes the distribution of anthropometric
measurements overall and by gender. The mean WHR for the
entire cohort was 0.95 (males 0.96, females 0.87). These data are
in accordance with the known patterns of obesity among men and
women: men had higher waist and abdominal circumferences
pointing towards central adiposity while females had higher hip
and thigh circumferences. The correlation between baseline BMI
and WHR was relatively weak (r=0.20; p-value=0.001) suggest-
ing that these parameters could be jointly evaluated with respect to
their EA risk.
Fourteen persons had less than five months of follow-up, during
which 11 were diagnosed with cancer. These 14 participants were
excluded from the main statistical analyses (Tables 3,4,5) due to an
a priori concern that cancers found during this early period of
intensive search for an occult cancer may have been present at
baseline. Analyses including all 411 participants were also
conducted and results are noted where different. The 397
participants accumulated 33,635 person-months (2802.9 person-
years; median 6.2 years, interquartile range 2.6–11.4 years) of
follow-up during which 45 developed EA.
The risk of progression to EA increased significantly with age
(HR=1.03 per year; 95%CI 1.00–1.06; p-trend=0.02) and this
association remained statistically significant after controlling for
gender (p-trend=0.014). Males were found to be at a non-
significantly higher risk for EA development than females
(HR=2.32; 95%CI 0.83–6.49).
The association between various cigarette smoking-related
measures and EA is described in Table 3. Smoking-related
parameters were computed on the basis of the participants’
responses at the baseline visit. Ever smokers of cigarettes were at
approximately 90% (HR=1.87, 95%CI 0.95–3.69) higher risk of
EA in univariate analyses. This association was attenuated
somewhat after control for the confounding effects of age, gender,
WHR and NSAID use (HR=1.57, 95%CI 0.78–3.14). Fully-
adjusted analyses which examined dose-response relationships
revealed statistically-significant trends with smoking duration
(ptrend=0.05) and cumulative exposure (ptrend=0.04), but not
with a summary measure of intensity (ptrend=0.10). As compared
to never-smokers, the HR for those in the highest tertile for pack-
years of cigarette smoking was 2.29 (95%CI 1.04–5.07). We found
no evidence that cigarette smoking cessation prior to baseline
evaluation was associated with decreased risk (ptrend=0.97).
Table 1. Selected characteristics of all participants in the
SBES cohort at baseline.
Total (n=411)
Males
(n=334)
Females
(n=77)
Number % Number % Number %
Age (years)
30–44.9 30 7.3 25 7.5 5 6.5
45–54.9 97 23.6 83 24.9 14 18.2
55–64.9 110 26.8 84 25.2 26 33.8
65–74.9 114 27.7 93 27.8 21 27.3
$75 60 14.6 49 14.7 11 14.3
Race
White 397 96.6 324 97.0 73 94.8
Non-white 14 3.4 10 3.0 4 5.2
BMI (kg/m
2)
#25 56 13.6 41 12.3 15 19.5
25.1-#30 194 47.2 167 50.0 27 35.1
30.1-#35 125 30.4 102 30.5 23 29.9
.35 36 8.8 24 7.2 12 15.6
Cigarette smoking
Current 40 9.7 28 8.4 12 15.6
Former 223 54.3 192 57.5 31 40.3
Never 148 36.0 114 34.1 34 44.1
NSAID use
{
Current 169 41.1 145 43.4 24 31.2
Former 79 19.2 58 17.4 21 27.3
Never 162 39.4 130 38.9 32 41.6
Alcohol (drinks/day)
0 76 18.5 52 15.6 24 31.2
0.01–1.00 134 32.6 102 30.5 32 41.6
1.01–2.99 93 22.6 80 24.0 13 16.9
$3.00 108 26.3 100 29.9 8 10.4
{Current NSAID use history for one male participant was missing.
doi:10.1371/journal.pone.0052192.t001
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between smoking and EA risk (Data not shown).
Table 4 presents results regarding alcohol consumption and EA
risk. In a model adjusted for age, gender, WHR, cigarette smoking
and NSAID use, we found no association between drinking three
or more alcoholic drinks per day and EA risk (HR=1.00; 95%CI
0.37–2.69; ptrend=0.80). We further examined this association by
beverage type and found no evidence of increasing EA risk with
increasing intake of beer or hard liquor. Although wine intake of
up to one drink/day tended to decrease the risk associated with EA
development, this decrease in risk was not statistically significant in
univariate or adjusted models. Main analyses involving smoking
and alcohol intake were repeated on the entire cohort of 411
persons (i.e. after including the 14 participants with 5 months or
less of follow-up) but the overall results remained the same.
In analyses of anthropometry (Table 5), three sets of models
were examined: unadjusted, adjusted for age and gender, and
adjusted for age, gender, cigarette smoking and NSAID use. BMI
was not associated with an increased EA risk in any of the analyses,
whether modeled as a continuous or categorical variable. In
addition, no substantial gender differences in the BMI-EA
association were observed (Data not shown). We observed a
significant trend (ptrend=0.01) between increasing WHR and EA
risk in univariate analyses, but adjustment for the confounding
effects of age, gender, smoking and NSAID attenuated the
association substantially such that the association was no longer
statistically significant (ptrend=0.16) (HR=1.48; 95%CI 0.60–
3.61, comparing extreme quartiles). Each of the four confounding
variables contributed somewhat to the attenuation in HR, with no
one variable predominating. The suggestive increased risk in the
adjusted models was observed only among males (HR=1.53;
95%CI 0.59–3.96; ptrend=0.12) but not in females (HR=0.95;
95%CI 0.05–18.92). Similar results as with WHR were obtained
when waist and abdominal circumferences were evaluated for
their relationship with EA, with an indication of a modest non-
statistically significant increase in risk for the uppermost quartile
(Data not shown). As with WHR, the increased risk of EA for both
waist and abdominal circumferences was observed only among
males, with no association in females. There was no suggestion of
an association between EA risk and hip circumference either in the
entire cohort or when the genders were evaluated separately (Data
not shown).
We conducted exploratory analyses to examine whether the
observed association with WHR among males varied by smoking
status or age of the participants. In models adjusted for age and
NSAID use, the elevated risk associated with men in the highest
WHR quartile was only apparent among never smokers of
cigarettes (Adjusted HR=6.17; 95%CI 0.61–62.43; ptrend=0.20)
and not among regular cigarette smokers (Adjusted HR=1.10;
95%CI 0.39–3.12; ptrend=0.26). Additionally, the increase in EA
risk associated with highest WHR quartile was greater among men
under 61.5 years (Adjusted HR=3.18; 95%CI 0.56–17.90;
ptrend=0.26) than among men over 61.5 years (Adjusted HR
1.24; 95%CI 0.40–3.79; ptrend=0.21). While suggestive, these
differences observed in the associations between WHR and EA by
smoking status and age were not statistically significant and should
be interpreted with caution due to the limited sample sizes
involved (pinteraction=0.50 and 0.34, respectively).
Of the 397 participants included in the above analyses, 17
(4.3%) received interventions such as mucosal ablation or
endoscopic mucosal resection, an endoscopic therapy for the
treatment of dysplastic changes in BE, prior to the end of their
follow-up. To ensure that such interventions did not bias the
reported HRs, we repeated the above analyses (Tables 3,4,5) after
excluding people who underwent such treatments. The results for
the remaining participants did not differ in important ways from
the associations observed in the main statistical analysis (Data not
shown). Of the original 411 participants, 103 (24.3%) individuals
were already under surveillance before the start of the epidemi-
ologic aspects of the study in 1995. To examine whether these
participants, who may have had BE for a longer period of time
than those participants newly entering the surveillance program,
differed with respect to the role of obesity and cigarette smoking,
we conducted sensitivity analyses dropping these 103 individuals
and repeating statistical analyses in Tables 3,4,5. We found that
while the associations with WHR were slightly stronger and those
with cigarette smoking weaker in comparison to the main
statistical analysis, none of the differences were statistically
significant and the overall conclusions remained the same.
Discussion
This prospective cohort study is one of the first to examine the
independent and joint associations between cigarette smoking,
alcohol, BMI and central adiposity and risk of neoplastic
progression among persons diagnosed with BE. We observed a
statistically-significant dose-response relationship with pack-years
of smoking and smoking duration, but no apparent beneficial
effect of smoking cessation. No evidence was found that alcohol
consumption increased EA risk, when tested as total alcohol intake
or by individual beverage type. We also found no indication that
BMI was predictive of EA development. Rather, we found
suggestive evidence that measures of central (abdominal) obesity,
Table 2. Anthropometric measurements of all participants in
the SBES cohort at baseline.
Entire cohort Males Females
(n=411) (n=335) (n=76)
No. Mean No. Mean No. Mean
Waist-Hip ratio
{ Q1 102 0.86 83 0.90 19 0.78
Q2 102 0.93 83 0.95 19 0.84
Q3 102 0.97 83 0.98 19 0.89
Q4 103 1.02 83 1.03 20 0.96
Waist
circumference
{
Q1 102 34.42 83 35.78 19 30.48
Q2 102 38.42 82 38.75 19 35.34
Q3 100 40.83 84 41.19 19 39.43
Q4 105 45.17 83 45.50 20 43.63
Hip
circumference
{
Q1 102 37.98 82 38.24 17 36.57
Q2 102 40.58 84 40.57 21 40.39
Q3 102 42.66 83 42.54 19 43.85
Q4 103 46.85 83 45.86 20 50.38
{Two males had missing waist and hip circumferences at baseline.
Q1: Quartile 1, Q2: Quartile 2, Q3: Quartile 3, Q4: Quartile 4.
Waist-Hip ratio- Entire cohort: Q1 0.72-, Q2 0.91-, Q3 0.95-, Q4 0.99-; Males: Q1
0.72-, Q2 0.93-, Q3 0.96-, Q4 1.00-; Females: Q1 0.72-, Q2 0.81-, Q3 0.87-, Q4 0.91-.
Waist circumference – Entire chort: Q1 25.5-, Q2 37.1-, Q3 39.6-, Q4 42.5-; Males:
Q1 25.5-, Q2 37.6-, Q3 39.8-, Q4 42.6-; Females: Q1 25.5-, Q2 33.5-, Q3 37.9-, Q4
40.8-.
Hip circumference - Entire chort: Q1 32.0-, Q2 39.5-, Q3 41.7-, Q4 43.9-; Males:
Q1 32.0-, Q2 39.6-, Q3 41.7-, Q4 43.4-; Females: Q1 32.0-, Q2 39.0-, Q3 41.8-, Q4
40.8-.
doi:10.1371/journal.pone.0052192.t002
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modestly increase EA risk. The non-statistically significant
increases we observed were stronger among males.
Cigarette smoking has long been known to be a major risk factor
for esophageal squamous cell carcinoma; early reports examining
the histology-specific relative risk estimates indicated a significant,
but more modest role for smoking in EA [24]. Subsequent
population-based case-control and cohort studies and a large
pooled analysis based in the Barrett’s and Esophageal Adenocar-
cinoma Consortium (BEACON) have since confirmed an
approximately two-fold increase in risk among ever-smokers, with
a strong and significant dose-response relationship with cumulative
exposure, yielding a relative risk estimate of 2.7 (95%CI 2.2–3.4)
among those with 45 or more pack-years of smoking [25].
The above studies examine the overall effect of smoking on EA
development. Several case-control studies have also examined the
association between smoking and development of BE, representing
an intermediate stage in EA development [26,27,35,36]. Three of
these studies have observed statistically significant increases in risk
among those in the highest cumulative exposure (pack-years)
category, ranging from 1.7 to 2.5 [26,27,36] whereas a fourth [35]
observed a more modest and non-significant 30% increased risk.
Our results, which indicate that high cumulative smoking
exposure also raises risk of neoplastic progression from BE to EA
(adjusted HR=2.3), begin to fill in some gaps with regard to the
overall role of smoking in EA development and the stages at which
it acts among those already diagnosed with BE. Specifically, it
appears that cigarette smoking likely plays roles of similar
magnitude in both the development of BE and progression from
BE to EA. This observation is in line with a recent study by
Coleman et al. that reported a 2-fold increase in EA risk associated
with current smoking among patients with BE [28]. The frequent
observation that smoking cessation reduces EA risk only modestly
and after many years is also consistent with a role of smoking in BE
development, which can occur decades before EA diagnosis
[25,37]. The specific mechanisms by which smoking increases risk
of both development of BE and progression from BE to EA are
unknown, but may be a combination of exposure to chemicals
such as N-nitrosoamines [38,39], the promotion of GERD
through the relaxing effects of tobacco smoke on the lower
esophageal sphincter [40], and the continued inflammatory effects
of smoking which promote cellular proliferation [7].
As with smoking, alcohol consumption is a strong established
risk factor for esophageal squamous cell carcinoma [41,42]. In
contrast, there is little evidence to suggest that total alcohol
consumption, or specific alcoholic beverages, modifies risk of EA
in the general population. A pooled analysis of 1,821 EA cases and
10,854 controls in BEACON revealed an odds ratio of 0.97
(95%CI 0.68–1.36) among the heaviest drinkers, in marked
contrast to the association with esophageal squamous cell
Table 3. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of esophageal adenocarcinoma among cigarette smokers
in the SBES cohort.
EA/total Unadjusted HR(95% CI)
Adjusted for age
{ and
gender HR(95% CI)
Adjusted for age
{,
gender, WHR
{ and
NSAID use
" HR(95% CI)
Ever use
Never 11/144 REF REF REF
Ever 34/253 1.87 (0.95–3.69) 1.72 (0.87–3.41) 1.57 (0.78–3.14)
Duration (years)
Nonsmokers 11/144 REF REF REF
T1 (0.5-,17) 9/83 1.46 (0.60–3.53) 1.49 (0.61–3.60) 1.41 (0.58–3.42)
T2 (17-,31) 10/82 1.54 (0.66–3.64) 1.43 (0.61–3.39) 1.30 (0.54–3.11)
T3 (31+) 15/88 2.71 (1.24–5.91) 2.25 (1.02–4.94) 2.00 (0.89–4.46)
p-value trend* 0.003 0.03 0.05
Intensity
Nonsmokers 11/144 REF REF REF
,1 pack/day 8/87 1.18 (0.47–2.93) 1.16 (0.47–2.88) 1.04 (0.41–2.59)
1 pack/day 13/71 2.64 (1.18–5.90) 2.28 (1.02–5.13) 2.17 (0.96–4.95)
.1 pack/day 13/95 2.01 (0.90–4.49) 1.84 (0.82–4.13) 1.68 (0.74–3.82)
p-value trend* 0.02 0.07 0.10
Cumulative exposure (pack-years)
Nonsmokers 11/144 REF REF REF
T1 (0.05-,14) 7/84 1.07 (0.41–2.75) 1.08 (0.42–2.80) 1.04 (0.40–2.69)
T2 (14-,36) 11/84 1.75 (0.76–4.03) 1.64 (0.71–3.80) 1.43 (0.61–3.37)
T3 (36+) 16/85 3.02 (1.40–6.50) 2.48 (1.14–5.42) 2.29 (1.04–5.07)
p-value trend* 0.002 0.02 0.04
{– Age modeled as a continuous variable,
{– WHR modeled as a continuous variable,
"– NSAID use modeled as a categorical variable (Current, Former, never).
T1: Tertile 1, T2: Tertile 2, T3: Tertile 3.
*Test for trend was based on the likelihood-ratio test associated with addition of the variable under consideration in its continuous form.
doi:10.1371/journal.pone.0052192.t003
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same analysis [43]. Fewer studies have examined the relationship
between alcohol intake and risk of BE in the general population,
but these also suggest no relationship [44–46]. There is little
previous data examining the possible role of alcohol in the
progression from BE to EA. However, our study, in combination
with the large pooled analysis of EA risk in population-based
studies, indicates that alcohol intake should not be a target for
prevention activities.
The important role that obesity plays in EA development was
recently summarized by Lagergren et al. [47], and has been
confirmed in numerous population-based case-control and cohort
studies [7,24,35,48–54]. Case-control studies generally rely on
recalled height and body-weight at various points in participants’
lives, since anthropometric measurements after cancer diagnosis
will often be modified by the cancer’s wasting effects; therefore
they cannot address the relative importance of weight (or BMI)
and central adiposity. One cohort study with multiple pre-cancer
measurements available found similar increased risk for BMI,
WHR, waist circumference and fat mass [51]. However this study
was limited by the small number of cancers observed, necessitating
the combination of gastric cardia (n=19) and EA (n=11) in the
analyses. Another cohort study had pant/skirt size available as
proxy measures for waist circumference. Both BMI and pant/skirt
size were significantly associated with risk of EA when analyzed
separately; models adjusted for both factors suggested that BMI
was more important although neither of the trend tests were
significant [46]. Similarly, results from the EPIC cohort suggest
that both BMI and abdominal obesity are important in EA
development [52]. Case-control studies of BE as an outcome
generally indicate that measures of abdominal obesity outweigh
BMI in terms of strength of association with BE [26,55]. Similar
results were observed in a nested case-control study within a large
cohort with pre-diagnostic measures of abdominal diameter [56],
and a small clinical study where visceral fat was measured using
computerized tomography [57].
Thus the relative roles of increased weight per se and abdominal
obesity remain unclear. Overall, previous studies suggest that the
effects of abdominal obesity are relatively strong with regard to the
development of BE, and predominate over BMI. The present
study suggests that, with regard to neoplastic progression to EA in
persons with BE, the effects of abdominal obesity also predominate
Table 4. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of esophageal adenocarcinoma for alcohol intake in the
SBES cohort.
EA/Total Unadjusted HR(95% CI)
Adjusted for age
{, gender,
WHR
{ and NSAID use
" HR
(95% CI)
Adjusted for age
{, gender,
WHR
{, NSAID use
" and
cigarette smoking
J HR
(95% CI)
Total alcohol (drinks/day)
0 8/75 REF REF REF
.0–1 9/135 0.63 (0.24–1.62) 0.65 (0.25–1.68) 0.56 (0.21–1.50)
.1–3 16/102 1.47 (0.63–3.44) 1.43 (0.60–3.45) 1.24 (0.50–3.08)
.3 12/85 1.35 (0.55–3.30) 1.23 (0.48–3.14) 1.00 (0.37–2.69)
p-value trend* 0.770 0.941 0.800
Beer (drinks/day)
0 12/143 REF REF REF
.0–1 21/171 1.57 (0.77–3.18) 1.61 (0.76–3.43) 1.43 (0.65–3.17)
.1–3 8/47 1.97 (0.80–4.81) 1.79 (0.69–4.61) 1.57 (0.59–4.19)
.3 4/33 1.53 (0.49–4.76) 1.53 (0.46–5.05) 1.34 (0.39–4.57)
p-value trend* 0.679 0.877 0.941
Wine (drinks/day)
0 27/214 REF REF REF
.0–1 16/163 0.75 (0.40–1.39) 0.70 (0.37–1.30) 0.68 (0.37–1.27)
.1–3 2/16 1.33 (0.32–5.61) 1.19 (0.28–5.02) 1.35 (0.32–5.74)
.3 0/2 - - -
p-value trend* 0.372 0.100 0.101
Liquor (drinks/day)
0 11/138 REF REF REF
.0–1 21/185 1.41 (0.68–2.93) 1.29 (0.62–2.71) 1.17 (0.54–2.53)
.1–3 9/45 3.06 (1.27–7.39) 2.86 (1.17–7.01) 2.51 (0.99–6.38)
.3 4/24 1.83 (0.58–5.74) 1.40 (0.42–4.62) 1.27 (0.38–4.27)
p-value trend* 0.107 0.310 0.417
{– Age as a continuous variable,
{–WHR as a continuous variable,
"– NSAID use as a categorical variable (Current, Former, never),
J– Smoking as a categorical variable (Ever, never).
*Test for trend was based on the likelihood-ratio test associated with addition of the variable under consideration in its continuous form.
doi:10.1371/journal.pone.0052192.t004
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several potential mechanisms which may be involved. First,
deposition of abdominal fat may lead to increased intra-abdominal
pressure which may directly cause gastro-esophageal reflux, a well-
established risk factor for BE and EA [7,58]. Second, adipose
tissue is metabolically active, secreting pro-inflammatory cytokines
and adipokines, which can promote cellular proliferation, reduce
apoptosis, and trigger neoplastic transformation in the esophageal
epithelium [7,59,60]. Results from the present report are
consistent with a previous case-control study that suggested the
relationship between obesity and EA may depend on the smoking
status and age of the individual, with increased association
between EA risk and obesity among non-smokers and younger
individuals [61]. It is notable that the gender differences in EA risk
observed in this study are consistent with the known demographics
of the disease and can partly be explained by the characteristic
abdominal distribution of fat seen in males as well as increased
prevalence of smoking among males.
Our study has several strengths, the most important one being
its prospective design. Additionally, misclassification of exposure
status was minimized by measurement of central adiposity by
trained staff, in contrast to use of self-reported data limited to BMI
in some previous studies. Comprehensive information on various
parameters of smoking and alcohol consumption before occur-
rence of EA enabled us to characterize these behaviors adequately
and limit confounding. In main analyses, we also excluded cases of
EA that occurred within the first 5 months of follow-up, thus
Table 5. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of esophageal adenocarcinoma (EA) for BMI and waist-hip
ratio (WHR) in the SBES cohort.
EA/total
Unadjusted HR
(95% CI)
Adjusted for age
{ and
gender HR(95% CI)
Adjusted for age
{, gender,
cigarette smoking
{ and
NSAID
" use HR(95% CI)
BMI
BMI continuous 45/397 0.99 (0.93–1.07) 1.02 (0.95–1.10) 1.01 (0.94–1.10)
BMI categories
#25 6/54 REF REF REF
.25-#30 22/188 0.91 (0.37–2.24) 1.00 (0.40–2.49) 0.88 (0.35–2.19)
.30-#35 13/120 0.84 (0.32–2.22) 0.99 (0.37–2.63) 0.81 (0.31–2.18)
.35 4/35 0.86 (0.24–3.05) 1.33 (0.36–4.89) 1.21 (0.32–4.48)
p-value trend* 0.85 0.61 0.73
WHR
WHR male & female
Q1 8/99 REF REF REF
Q2 12/99 1.67 (0.68–4.09) 1.58 (0.64–3.88) 1.38 (0.56–3.40)
Q3 12/97 1.46 (0.60–3.58) 1.40 (0.57–3.44) 1.24 (0.50–3.05)
Q4 13/100 1.88 (0.78–4.55) 1.61 (0.66–3.92) 1.48 (0.60–3.61)
p-value trend* 0.01 0.12 0.16
Q2–Q4 37/294 1.66 (0.77–3.56) 1.53 (0.71–3.29) 1.36 (0.63–2.94)
WHR male
Q1 7/82 REF REF REF
Q2 11/80 1.84 (0.71–4.75) 1.67 (0.65–4.34) 1.44 (0.55–3.76)
Q3 11/78 1.62 (0.63–4.19) 1.50 (0.58–3.88) 1.32 (0.51–3.44)
Q4 12/82 1.98 (0.78–5.04) 1.72 (0.67–4.40) 1.53 (0.59–3.96)
p-value trend* 0.04 0.08 0.12
Q2–Q4 34/238 1.81 (0.80–4.08) 1.63 (0.72–3.69) 1.42 (0.62–3.26)
WHR female
Q1 1/17 REF REF REF
Q2 1/19 0.87 (0.05–13.94) 1.03 (0.06–16.77) 3.01 (0.09–99.07)
Q3 1/19 0.71 (0.04–11.39) 0.77 (0.05–12.45) 0.82 (0.05–13.62)
Q4 1/18 1.21 (0.07–19.69) 0.91 (0.05–15.19) 0.95 (0.05–18.92)
p-value trend* 0.97 0.86 0.75
Q2–Q4 3/56 0.89 (0.09 –8.54) 0.89 (0.09–8.59) 1.04 (0.10–10.96)
{– Age modeled as a continuous variable,
{– Cigarette smoking modeled as a categorical variable (Current, Former, Never),
"– NSAID use modeled as a categorical variable (Current, Former, Never).
Q1: Quartile 1, Q2: Quartile 2, Q3: Quartile 3, Q4: Quartile 4.
*Test for trend was based on the likelihood-ratio test associated with addition of the variable under consideration in its continuous form.
doi:10.1371/journal.pone.0052192.t005
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previous studies that were unable to account for this bias [52].
While substantially larger than other well-characterized pro-
spective cohort studies with anthropometric measures, the
relatively small number of incident cases is an important
limitation, leading to imprecise estimates, especially for the
evaluation of effect modification. Additionally, we will not have
captured all the incident cases of EA that occurred among our
participants as follow-up ended with cessation of active surveil-
lance. As some of the cohort members were being followed prior to
1995 (baseline evaluation for the purposes of this manuscript), our
analyses included a mix of prevalent and incident cases of BE. This
is a limitation of most studies of BE, as BE is an endoscopic
diagnosis and the exact date of disease is rarely known. Another
potential limitation is the possibility of residual confounding due to
measured or unmeasured risk factors. In particular, we lacked data
on Helicobacter pylori status, which could possibly confound the
WHR-EA association. Not only has H.pylori been shown to
decrease body weight by suppressing appetite, but it is also been
observed in multiple population-based studies to be inversely
related to risk of EA [62–64]. Finally, as our participants are from
a specialized and relatively high-risk cohort of persons with
histologically confirmed BE, the results presented in this report
cannot necessarily be generalized to persons with BE in the
general population or considered to be representative of the
natural history of EA. Rather these estimates should be interpreted
as describing the risk of progression to EA once diagnosed with
BE.
In summary, we observed a statistically significant dose-response
relationship with cigarette smoking pack-years as well as duration.
We did not observe any association with alcohol intake or BMI.
We also found that abdominal obesity, measured as WHR, may be
modestly useful in predicting neoplastic progression to EA among
Barrett’s patients, especially among males. Further epidemiolog-
ical studies with larger number of EA cases are required to validate
these findings, especially among subgroups of people with BE in
order to better understand the mechanisms by which tobacco and
perhaps obesity increase the risk of neoplastic progression among
Barrett’s esophagus patients and their potential role in EA
prevention.
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